Monte Rosa Therapeutics announced the pricing of an underwritten public offering of 11.125 million common shares and 1.375 million pre-funded warrants, expected to generate approximately $300 million in gross proceeds. The company also granted underwriters a 30-day option to purchase up to an additional 1.875 million shares. Joint book-running managers for the deal include Jefferies, TD Cowen and Piper Sandler, with Wedbush PacGrow and LifeSci Capital acting as passive bookrunners. The offering, conducted under an SEC-declared shelf registration, is slated to close on January 12, 2026, subject to customary closing conditions, and will fund the advancement of Monte Rosa’s pipeline of molecular glue degrader candidates.

Monte Rosa’s stock climbed by 45% following interim Phase I data for MRT-8102 in patients with inflammatory conditions. In a 24-patient cohort, MRT-8102 achieved an average NEK7 degradation of 70%, accompanied by a 55% mean reduction in C-reactive protein levels after four weeks of dosing. The drug demonstrated a favorable safety profile, with no dose-limiting toxicities reported up to the highest tested dose of 200 mg once daily. These findings support the potential of MRT-8102 to address inflammatory pathways that have eluded other small-molecule approaches, fueling investor optimism and bolstering the company’s valuation.